Loading stock data…
ZVRA
$13.66+1.57 (+12.99%)
Market ClosedLast close Jun 9
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zevra Therapeutics, Inc. in the Healthcare sector is trading at $13.66. Wall Street consensus targets $23.00 (9 analysts), implying a +68.4% move over the next 12 months. The stock is currently near its 52-week high of $13.80, remaining 44.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +68.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$13.66
Potential Downside
0%
Whystock Fair Value$13.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.36%
Volume
Today's trading volume
4.99M
Recent News
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?
Zevra Therapeutics recently submitted U.S. Patent No. 11,707,456 for its approved Niemann-Pick type C treatment MIPLYFFA to the FDA’s Orange Book, aiming to secure patent protection until 2041 and reinforce barriers to generic competition. This move strengthens Zevra’s intellectual property position around its only FDA-approved medicine, potentially extending the period during which it can exclusively commercialize MIPLYFFA. We’ll now examine how this extended MIPLYFFA patent protection to...
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?
Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
Zevra said in a statement that it has asked the U.S. Food and Drug Administration to add its new patent for its drug MIPLYFFA to its official list.
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041
Zevra Therapeutics (NASDAQ:ZVRA) said it has submitted a patent covering its product MIPLYFFA for listing in the US Food and Drug Administration's Orange Book, with patent protection extending to 2041. The submission seeks to list the patent in the Orange Book, the FDA's register of approved...
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear
Even though Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) posted strong earnings recently, the stock hasn't reacted in a...